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 Allele-specific long-distance regulation dictates IL-32
isoform switching and mediates susceptibility to HIV-1
Robert-Jan Palstra,1* Elisa de Crignis,1 Michael D. Röling,1 Thomas van Staveren,1 Tsung Wai Kan,1
Wilfred van Ijcken,2 Yvonne M. Mueller,3 Peter D. Katsikis,3 Tokameh Mahmoudi1*
We integrated data obtained from HIV-1 genome-wide association studies with T cell–derived epigenome data and
found that the noncoding intergenic variant rs4349147, which is statistically associated with HIV-1 acquisition, is
located in a CD4+ T cell–specific deoxyribonuclease I hypersensitive region, suggesting regulatory potential for this
variant. Deletion of the rs4349147 element in Jurkat cells strongly reduced expression of interleukin-32 (IL-32),
approximately 10-kb upstream, and chromosome conformation capture assays identified a chromatin loop be-
tween rs4349147 and the IL-32 promoter validating its function as a long-distance enhancer. We generated single
rs4349147-A or rs4349147-G allele clones and demonstrated that IL-32 enhancer activity and interaction with
the IL-32 promoter are strongly allele dependent; rs4349147 −/A cells display reduced IL-32 expression and altered
chromatin conformation as compared to rs4349147 G/− cells. Moreover, RNA sequencing demonstrated that
rs4349147 G/− cells express a lower relative ratio of IL-32a to non-a isoforms than rs4349147 −/A cells and display
increased expression of lymphocyte activation factors rendering them more prone to infection with HIV-1. In agree-
ment, in primary CD4+ T cells, both treatment with recombinant IL-32g (rIL-32g) but not rIL-32a, and exogenous
lentiviral overexpression of IL-32g or IL-32b but not IL-32a resulted in a proinflammatory T cell cytokine environment
concomitant with increased susceptibility to HIV infection. Our data demonstrate that rs4349147-G promotes
transcription of non–IL-32a isoforms, generating a proinflammatory environment more conducive to HIV infection.
This study provides a mechanistic link between a HIV-associated noncoding DNA variant and the expression of dif-
ferent IL-32 isoforms that display discrete anti-HIV properties. //adv o
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Host genetic variation has long been recognized to play a major role in
HIV-1 infection susceptibility and disease progression (1). Although it
is widely accepted that genetic variants in loci encoding class I human
leukocyte antigens (HLAs) and the chemokine receptor CCR5 have a
major impact on HIV infection, the contribution of additional genetic
variants remains elusive. In the past decade, genome-wide association
studies (GWASs) have attempted to identify single-nucleotide poly-
morphisms (SNPs) that are correlated with various aspects of HIV dis-
ease acquisition or progression. In general, a major limitation of GWAS
is that they are geared to identify genetic variants with relatively high
minor allele frequencies andmoderate to high effects, particularly when
the sample size is small. This is especially the case for HIV-1 GWAS (1)
where collection of large cohorts is challenging. As a consequence,
common variants with weak effect size and rare variants fall below
the stringent threshold for genome-wide significance (P < 5 × 10−8)
and are missed. In addition, the functional significance of identified
HIV-associated genetic variants is often unclear because most of the
correlated SNPs locate to noncoding regions of the genome with un-
known function (1). As a consequence, HIV-centered GWASs fail to
deliver distinct candidate loci, which hampers further efforts to char-
acterize the contribution of human genetic variation to HIV suscepti-
bility and disease progression. Integration of additional approaches to
prioritize candidate loci is therefore of utmost importance to push the
field of HIV-1 host genetics forward.Recently, it is becoming clear that inclusion of genome-wide func-
tional data into the analysis can circumvent the caveats of GWAS,
allowing the identification of candidate noncoding SNPs most likely
to be biologically relevant. As we have shown for the pigmentation-
associated variant rs12913832 (2), function can be inferred for noncod-
ing SNPs by examining co-occurrence with chromatin marks generally
associated with regulatory DNA elements using resources that include
the Encyclopedia of DNA Elements (ENCODE) and the Human Epi-
genome Atlas, among others (3). Thus, epigenomic data are used to
identify variants with potential function and strongly reduce the list
of noncoding SNPs to analyze. This analysis can also identify the rele-
vant cell types and candidate genes to be investigated. Promising can-
didate variants are subsequently scrutinized by detailed molecular
analysis to elucidate their biological function. Crucially, it was recently
demonstrated that such an approach can also prioritize so-called “sub-
threshold” variants that fail to reach the widely accepted threshold of
P < 5 × 10−8 statistical significance and assign biological function to
them (3). A total of 72% of the subthreshold loci that were prioritized
in this way contained an allele-specific enhancer, and they were also
more likely to replicate in subsequent GWASs than subthreshold loci
that do not overlap active enhancers.
Here, we integrated data obtained fromHIV-1 GWASs with T cell–
derived epigenome data to identify noncoding HIV-1–associated SNPs
with potential regulatory function. We performed a detailed molecular
analysis of one of the identified variants, rs4349147, which is statistically
associated at a subthreshold level with HIV-1 acquisition (4), and dem-
onstrated that this variant is located in a lymphoid-specific enhancer for
the interleukin-32 (IL-32) cytokine gene. Haplotypes of rs4349147 not
onlymodulate the transcription level of IL-32 but also alter the ratio of
isoforms expressed. This altered expression of IL-32 isoforms modu-
lates the expression of proinflammatory factors that modify suscepti-
bility toHIV-1 infection.Our study demonstrates that the integration of1 of 13
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 RESULTS
Deoxyribonuclease I hypersensitive region encompassing
rs4349147 is a long-distance enhancer of IL-32
As a starting point for this study, we collected publishedHIV-associated
variants (P < 9 × 10−6) from the GWAS catalog (www.ebi.ac.uk/gwas/;
accessed onMay 2014), together with SNPs in strong linkage (r2 > 0.8).
Because deoxyribonuclease I (DNase I) “hypersensitivity” is a feature of
active cis-regulatory sequences in a given cell type, we compared the
HIV-associated variants toDNase I hypersensitivity data obtained from
CD4+ T helper naïve (TH0) and TH1 cells [ENCODE data set; Univer-
sity of California, Santa Cruz (UCSC) genome browser]. This analysis
yielded a list of 21 HIV-associated SNPs that are located in potential
regulatory regions (table S1). Most of these SNPs are located on chro-
mosome 6 with the majority spread out more than a 1.3-Mb region en-
compassing the HLA loci, a thoroughly studied region and well known
to be associated with HIV infection. Four SNPs are located in a histone
cluster, whichwe reasoned to be of less interest. Two SNPs are located in
a 500-kb gene desert on chromosome 1 and two in a 175-kb gene desert
on chromosome 8. The remaining three variants are located in a gene-
dense region on chromosome 16, and we decided to investigate this
region in more detail. The three variants located on chromosome 16
(rs12447486, rs2015620, and rs4349147) are in perfect linkage (HapMap
release 22; CEU), and rs4349147 has been reported to be associated at a
subthreshold level (P = 7.91 × 10−6) with HIV-1 acquisition in a cohort
of African HIV-1 serodiscordant heterosexual couples (4). rs4349147 is
located in a region that is strongly DNase I–hypersensitive in the T cell–
derived cell lines Jurkat and SupT1 but not in cells not belonging to the
immune compartment (Fig. 1A), whereas the other two variants are lo-
cated in regions with minimal DNase I hypersensitivity. In agreement,
formaldehyde-assisted isolation of regulatory elements (FAIRE) assays
demonstrated strong enrichment of the rs4349147DNA region in the T
cell lines but not in the unrelated G361melanoma cells (fig. S1A), high-
lighting the presence of an active regulatory element and supporting a
regulatory role for the rs4349147 region in T cells. To gainmore insight
into its function, we deleted the DNase I hypersensitive (DHS) region
containing rs4349147 using an upstream- and downstream-targeted
CRISPR (clustered regularly interspaced short palindromic repeats)–
Cas9 (CRISPR-associated protein 9) gene editing approach (Fig. 1B,
top). Polymerase chain reaction (PCR) confirmedhomozygous deletion
of the rs4349147 DHS (Fig. 1B, bottom), and a clonal Jurkat line con-
taining a full knockout (KO) of the rs4349147 DHS was generated. Se-
quencing confirmed the deletion of the specific region (fig. S1B).
To determine which genes are regulated by this DHS region, we per-
formed high-throughput sequencing of RNA isolated from wild-type
(WT) and rs4349147 DHS KO Jurkat cells. We found that of all genes
within a 500-kb region centered on rs4349147, specifically, the expression
of IL-32 is severely reduced uponKOof the rs4349147DHS (Fig. 1C and
fig. S1C), whereas the expression of surrounding genes remains essential-
ly unchanged (Fig. 1C and fig. S1D). We confirmed this observation by
reverse transcriptionPCR (RT-PCR) (Fig. 1D).Western blotting (Fig. 1E)
and intracellular flow cytometry (Fig. 1F) demonstrated that IL-32 expres-
sion at the protein level is, as expected, likewise reduced to undetectable
levels in the rs4349147 DHS KO cells. In addition, targeting of a deadPalstra et al., Sci. Adv. 2018;4 : e1701729 21 February 2018Cas9 (dCas9)–Kruppel-associated box (KRAB) fusion protein, which is a
strong repressor of enhancer function (5), to the rs4349147 DHS in WT
Jurkat cells also resulted in significant reduction of IL-32 RNA expression
(fig. S1E), supporting our observations in the rs4349147 KO cells.
Distal regulatory elements, such as enhancers, are known to com-
municate with their target genes through chromatin loop formation
(6). To determine whether chromatin at the rs4349147 DHS directly
contacts the IL-32 promoter, we performed chromosome conformation
capture (3C) analysis, which revealed the presence of a chromatin loop
between rs4349147 DHS and the IL-32 promoter in WT Jurkat and
SupT1 T cells (Fig. 1G). Together, these results demonstrate that the
DNA element encompassing rs4349147 is a strong long-distance
enhancer essential for the expression of IL-32 in CD4+ T cells.
IL-32enhanceractivity isdependenton the rs4349147haplotype
Jurkat cells are heterozygous rs4349147-G/A that allowed us to generate
heterozygous lines harboring a deletion of either the rs4349147-G or
rs4349147-A allele enhancer and thus generate single rs4349147-G (G/−)
or rs4349147-A (−/A) allele clones. rs4349147-G/A is inperfect linkage dis-
equilibrium (LD) with rs4786376-G/C, which is also situated in the IL-32
enhancer region (Fig. 2A). rs4786376-G/C can be used to genotype clones
by restriction fragment length polymorphism because the rs4786376-C
allele generates a uniqueNla III restriction site (Fig. 2, A toC). RNAand
protein expression levels of IL-32 in the single rs4349147G/− cells were
found to be similar to WT levels, whereas rs4349147 −/A cells display
significant reduction of IL-32 both at the RNA and protein level, as
determined by RT-PCR, Western blotting, and intracellular flow cy-
tometry (Fig. 2, D to F, and fig. S2A). Moreover, 3C analysis revealed
that the long-range interaction of the enhancer region with the IL-32
promoter region is significantly altered in rs4349147 −/A cells compared
to rs4349147 G/− Jurkat cells (Fig. 2G), suggesting a change in chromatin
conformation. To get a better understanding of which variant, rs4349147-
G/A or rs4786376-G/C, is responsible for the differential IL-32 expression,
we cloned enhancer fragments with different genotypes in an IL-32
promoter–driven luciferase reporter construct and determined their activ-
ity. The rs4349147-G allele induces luciferase expression 3.5-fold when
compared to the other haplotypes (Fig. 2H), suggesting that this variant
is responsible for the main activity of this regulatory element. To further
investigate the influence that the rs4349147and rs4786376variants haveon
the activity of the IL-32 regulatory element, we subjected the rs4349147
−/A clone to another round of CRISPR/Cas9 genome editing and ob-
tained a clone designated −/A Drs4349147 that harbored a 180–base
pair (bp) deletion that removed the rs4349147-A variant but left the
rs4786376-C variant in place (Fig. 2I and fig. S2B). Real-time PCR anal-
ysis of IL-32 expression in this clone revealed a significant 4.5-fold drop
in expression as compared to the parental rs4349147 −/A clone (Fig. 2J)
and confirmed that rs4349147 is the variant responsible for differential
IL-32 expression.We conclude that the activity and physical interaction
of the long-distance IL-32 enhancer element are strongly dependent on
the allelic status of rs4349147.
rs4349147 G/− Jurkat cells are more conductive to HIV
infection than rs4349147 −/A cells
When infected with a minimal HIV-derived virus, rs4349147 G/− Jur-
kat cells are more prone to infection than rs4349147 −/A Jurkat cells
(Fig. 3A). The observed differences in infection remained similar over
time and with different virus concentrations (fig. S3, A and B). These
results support the observations reported in a GWAS, indicating
that the rs4349147-G allele confers susceptibility to HIV infection (4).2 of 13
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 Fig. 1. DNA region encompassing rs4349147 is a strong enhancer element for the IL-32 gene in T cells. (A) UCSC genome browser tracks show that the HIV-associated variant
rs4349147 is located in a T cell–specific DHS region. Each track represents the DNase I accessibility profile for a given cell line. Promoters as defined by the Eukaryotic Promoter Database
(EPD; http://epd.vital-it.ch) are indicated as red bars. HUVEC, human umbilical cord endothelial cell. (B) Deletion of rs4349147 DHS. Location of small-guiding RNAs (sgRNAs) used in the
CRISPR-Cas9 KO strategy is indicated. Panels show results from two different PCR assays generating amplicons 1 or 2, as indicated, that confirm homozygous deletion of rs4349147 DHS.
(C) RNA expression levels of genes in a 500-kbwindow surrounding rs4349147 demonstrate a strong reduction in IL-32 expression. For each gene considered in the analysis, right panel
shows total number of reads, whereas left panel shows fold change in expression in rs4349147 DHS KO cells compared to WT. N/A, not available. (D to F) Strong reduction of IL-32
expression is confirmedusing real-timequantitativePCR (qPCR) (D),Westernblottingusinganantibodyagainst IL-32 (E), and intracellular stainingwithbiotin-conjugatedantibodyagainst
IL-32, followed by fluorescence-activated cell sorting (FACS) analysis (F). (G) 3C analysis of the IL-32 locus demonstrates chromatin loop formation between rs4349147 and the IL-32
promoter region in Jurkat and SupT1 cells. The analyzed region of the human IL-32 locus is depicted on the topof each graph. X axis shows the approximate positionon chromosome
16 (Chr 16) (UCSC genome browser GRCh37/hg19 assembly). Dark gray shading shows the position and size of the “fixed” Dpn II restriction fragment. Light gray shading indicates
position and size of other Dpn II restriction fragments analyzed. The Dpn II restriction fragment containing the IL-32 promoter is indicated in a slightly darker gray color.Palstra et al., Sci. Adv. 2018;4 : e1701729 21 February 2018 3 of 13
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 Fig. 2. Activity of the rs4349147 enhancer element is dependent on the haplotype. (A) Schematic representation of the region encompassing the rs4786376-G/C and
rs4349147-G/A SNPs, indicating the size of the PCR products obtained using primers outside (amplicon 1) or inside (amplicon 2) the region targeted for KO. Amplicon 2 contains
three Nla III restriction sites (asterisks). The central NIa III site (blue asterisk) includes the rs4786376-G/C SNP, which is in perfect linkage with rs4349147-G/A and can be used to
genotype the heterozygous lines. (B) Simultaneous presence of two PCR products of different sizes indicates the occurrence of heterozygous rs4349147 KO lines. (C) Results of
restriction reaction of amplicon 2 inWT (heterozygous rs4349147-G/A), rs4349147 −/A, G/−, or rs4349147 enhancer KO Jurkat lines. (D) Expression of IL-32mRNA in the four lines
was measured by real-time PCR. Cells homozygous for rs4349147-A express lower IL-32 RNA levels as compared to those homozygous for rs4349147-G. (E) IL-32 protein levels
were determined by Western blotting using an antibody against IL-32. (F) Intracellular staining with biotin-conjugated antibody against IL-32, followed by FACS analysis, shows
lower levels of IL-32 in rs4349147 −/A Jurkat cells and rs4349147 KO Jurkat cells as compared to WT and rs4349147 G/− Jurkat cells (Fig. 1F). (G) 3C analysis of the IL-32 locus
demonstrates chromatin loop formation between rs4349147-G and the IL-32 promoter region in rs4349147 G/− Jurkat cells and a significant reduction in enhancer-promoter
interaction in the rs4349147 −/A Jurkat cells. Ratio of interaction in rs4349147 −/A and G/− Jurkat cells is indicated. For further explanation of the figure, see Fig. 1G. (H) Activity of
476-bp enhancer fragments with different rs4349147 and rs4786376 genotypes in an IL-32 promoter–driven luciferase reporter construct. The rs4349147-G allele results in a
3.5-fold induction of luciferase expressionwhen compared to the other haplotypes. The rs4349147 and rs4786376 alleles present in the reporter construct are indicated below the
graph. (I) Schematic depicting the 158-bp deletion in the −/A Drs4349147 clone. (J) The 158-bp deletion in the −/A Drs4349147 clone reduces IL-32 expression 4.5-fold as
compared to IL-32 expression in the parental rs4349147 −/A Jurkat clone.Palstra et al., Sci. Adv. 2018;4 : e1701729 21 February 2018 4 of 13
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 Remarkably, deletion of the rs4349147 enhancer region did not result in
decreased susceptibility to HIV infection but displayed infection levels
similar to the rs4349147 G/A and G/− Jurkat cells (Fig. 3A). This phe-
notype was not due to a clonal effect in the rs4349147 −/− cells because
deletion of a 180-bp fragment that contains rs4349147-A variant from
the rs4349147 −/A Jurkat cells (−/A Drs4349147) reverted the low–
rs4349147 −/A HIV susceptibility phenotype to a high-susceptibility
phenotype, similar to the rs4349147 G/A, G/−, and −/− Jurkat cells
(Fig. 3A).
Alternative rs4349147 alleles differentially modulate the
relative expression of IL-32 isoforms
The observation that the rs4349147 KO cells −/− and −/A Drs4349147
display similar susceptibility to infection as G/A and G/− cells, despite
the fact that IL-32 expression is strongly reduced, compared to the less
susceptible rs4349147 −/A cells strongly suggested that the absolute
levels of IL-32 expression is not the key factor that determines suscep-
tibility to HIV infection. Multiple protein variants of IL-32 with differ-
ent but poorly characterized functions have been documented (Fig. 3B)
(7, 8). The five major protein isoforms of IL-32 (isoforms A to E) are
encoded by multiple RNA splice variants (variants 1 to 9). It is known
that these IL-32 isoforms affect the immune system and susceptibility to
HIV in different ways (8). In general, IL-32 isoforms are categorized as
proinflammatory (represented mainly by IL-32b and IL-32g) or non-
proinflammatory (mainly represented by IL-32a). Controlling the ex-
pression of these distinct isoforms, two different promoters are assigned
to the IL-32 gene by the EPD (http://epd.vital-it.ch). The upstream
promoter is designated EPD NK4_1, whereas the downstream
promoter is designated EPD IL32_1 (Fig. 1A). Promoter EPD NK4_1
generates long transcripts such as RNA variant 4 encoding the A iso-
form of IL-32 (IL-32a) and RNA variants 1, 2, and 8 encoding the B
isoform of IL-32 (IL-32b), whereas the downstream promoter EPD
IL32_1 generates shorter transcripts such as RNA variant 3 encoding
the main IL-32b, RNA variants 6 and 5 encoding the C isoform of
IL-32, RNA variant 7 encoding the D isoform, and RNA variant 9 en-
coding the isoform E precursor (IL-32g) (Figs. 1A and 3B).
The fact that alternative IL-32 isoforms with different effects on the
immune system are potentially expressed from two distinct promoters,
together with the observation that reduction in absolute IL-32 expres-
sion levels is likely not the key determinant of reduced HIV infection
susceptibility, we wondered whether the rs4349147 regulatory element
could differentially regulate the IL-32 promoters. Therefore, we ana-
lyzed the relative expression levels of distinct IL-32RNAvariants in data
obtained from high-throughput RNA sequencing (RNA-seq) in
rs4349147 G/A, G/−, or −/A and −/− cells (Fig. 3C). This analysis re-
vealed that, concurrent with a decrease in expression of IL-32, a switch
occurs in the ratio of isoforms; rs4349147 −/A cells display a shift from
“short” IL-32 variants originating from the EPD IL32_1 promoter to the
“longer” RNA variants originating from the EPDNK4_1 promoter, re-
sulting in a higher relative expression of the IL-32a–encoding RNAvar-
iant 4 (Fig. 3C). The higher relative expression of IL-32a is confirmed by
RT-PCR using primers specific for the IL-32a and non–IL-32a iso-
forms (fig. S3D) and ismatched by a relative increase in protein levels of
IL-32a in rs4349147 −/A cells, as demonstrated by Western blotting
using an IL-32a–specific antibody for detection (fig. S3, E and F). The re-
lative ratio of IL-32a over non–IL-32a expression does not change after
HIV infection of rs4349147 G/− and −/A cells (fig. S3G).
Relative IL-32 isoform expression in rs4349147KOcells−/− showed
a lower relative ratio of IL-32a expression, consistent with its similarPalstra et al., Sci. Adv. 2018;4 : e1701729 21 February 2018propensity to HIV infection to G/A and G/− cells but not to −/A cells
(Fig. 3, A to C). In agreement, in the −/A Drs4349147 KO line, both the
lower relative IL-32a–to–IL-32g ratio and the higher susceptibility to
HIV infection are similar to the rs4349147 G/− cells but not to the
−/A cells (Fig. 3D and fig. S3, D and E). The observed difference in in-
fection efficiency is independent from the envelope (Env) protein used
to generate the pseudoviral particles because rs4349147 −/A cells
infected with HIV-1 Env-pseudotyped virus still display a reduced in-
fection rate as compared to rs4349147 G/− or −/A Drs4349147 Jurkat
cells (Fig. 3E). Therefore, the allelic contribution to susceptibility does
not involve the interaction between gp120/gp41 and cellular receptor
and co-receptors but rather is mediated by a more general mechanism.
rs4349147 G/− Jurkat cells generate a proinflammatory T cell–
activating environment more conducive to HIV infection
To gain further insight into themechanism by which rs4349147-G pro-
motes HIV infection, we further analyzed the RNA-seq data obtained
from unstimulated, uninfected rs4349147 G/A, G/−, −/A, and −/− cells
(Fig. 3, F and G). We focused our analysis on genes differentially
expressed specifically between rs4349147 −/A, G/−, and G/A Jurkat
cells. We found that 97 genes are at least twofold up-regulated, whereas
152 genes are at least twofold down-regulated (Fig. 3F and table S2) in
rs4349147 −/A Jurkat cells as compared to rs4349147 G/A and G/−
Jurkat cells. Gene ontology (GO) biological process analysis of
down-regulated genes revealed overrepresentation of factors involved
in the regulation of cell activation (lymphocyte, leukocyte, and T cell),
consistentwith a relatively lower expression of proinflammatory IL-32
isoforms (Fig. 3G and table S3). RT-PCR confirmed the increased ex-
pression of T cell activation genes such as IL-4R (IL-4 receptor),
TFFRSF14, STAT5A (signal transducer and activator of transcription
5A), LGALS1, andANXA1 (fig. S4A) in theWTand rs4349147G/− cells.
Consistent with its reverted higher propensity for infection and increased
relative ratio of the proinflammatory IL-32 isoforms, the proinflamma-
tory gene expression profile is restored in the rs4349147 −/− KO cells
(Fig. 3F and fig. S4A). An enrichment in GO biological process analysis
was observed for the Wnt signaling pathway in up-regulated genes
(fig. S4, B and C). Factors previously reported to interact with HIV-1
(www.ncbi.nlm.nih.gov/genome/viruses/retroviruses/hiv-1/interactions/)
were also overrepresented (fig. S4D) in the list of down-regulated genes.
Cytokine array profiling using supernatants of rs4349147 G/− or −/A
Jurkat cultures demonstrates that, in linewith the known immunemod-
ulatory role of proinflammatory IL-32 isoforms, rs4349147 G/− cells
exhibit elevated secretion of several interleukins and other cytokines
(fig. S4E and table S4). Together, these experiments demonstrate that
Jurkat cells containing the rs4349147 G/− allele display an increased ex-
pression of proinflammatory genes and genes involved in T cell activa-
tion and proliferation when compared to rs4349147 −/A cells.
We determined the functional consequence of the observed shift in
IL-32 isoform expression in context of HIV infection by overexpression
of the distinct IL-32 isoforms in rs4349147 enhancer KO Jurkat cells,
which express low amounts of endogenous IL-32 (Figs. 1, D to F, and
2, D to F), followed by infection with vesicular stomatitis virus (VSV)–
pseudotyped HIV-derived virus (Fig. 3H). Expression of the distinct
IL-32 isoforms was confirmed by Western blotting (Fig. 3H, bottom)
and RT-PCR (fig. S4F). Exogenous expression of the IL-32 isoforms
B to E resulted in an increase in HIV infectability (Fig. 3H). In contrast,
when IL-32a (isoform A) was exogenously expressed, no increase in
HIV infection was observed. A similar pattern of susceptibility to infec-
tion was observed when IL-32 isoforms were overexpressed in WT5 of 13
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 Fig. 3. The rs4349147-G allele generates a proinflammatory activated T cell environment conducive toHIV infection. (A) Levels of infection,measured as fold increase in
the mean fluorescence intensity (MFI), in rs4349147 G/A, −/A, G/−, −/−, and −/A Drs4349147 Jurkat lines after challenge with minimal HIV vesicular stomatitis virus glycoprotein
(VSVG)–pseudotyped virus. rs4349147 −/A Jurkat cells have reduced susceptibility to infection compared to Jurkat cells with other rs4349147 genotypes. (B) Nine RNA variants of
IL-32 have been reported that encode for five different IL-32 protein isoforms [isoform A (IsoA), indicated in red; isoform B (IsoB), blue shades; isoform C (IsoC), green shades;
isoformD (IsoD), purple; and a precursor isoform E (IsoE precursor), black]. (C) IL-32 isoformA expression is relatively elevated in rs4349147−/A cells as compared to rs4349147WT
(G/A), G/−, or KO(−/−) cells. Bar charts show the contribution of each isoform to the total levels of IL-32 expression. (D) RT-PCR demonstrating a reduced ratio of IL-32a over IL-32g
transcripts upon deletion of the 180 bp rs4349147 containing region from the IL-32 regulatory element. (E) Levels of infection in rs4349147 −/A, G/−, and −/A Drs4349147 Jurkat
lines after challenge with HIV Env-pseudotyped virus. Luciferase activity obtained in rs4349147 G/− cells was set to 1. (F) RNA-seq heat map representation of differentially
expressed genes in rs4349147 G/A, G/−, −/A, and −/− Jurkat cell lines. High-throughput RNA-seq reveals that 97 genes are up-regulated, whereas 152 genes are down-regulated
at least twofold in rs4349147 −/A Jurkat cells when compared to rs4349147 G/− and WT (G/A) Jurkat cells. (G) GO-based functional classification of genes down-regulated in
rs4349147 −/A Jurkat cells compared to rs4349147 G/− Jurkat cells. (H) Levels of infection, measured as fold increase in the MFI, following exogenous expression of IL-32
isoforms A to E in rs4349147 enhancer KO cells. Color coding is as for (B). Bottom: Exogenous expression of IL-32 as determined byWestern blotting using the pan–IL-32 antibody.Palstra et al., Sci. Adv. 2018;4 : e1701729 21 February 2018 6 of 13
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 Jurkat cells expressing high levels of IL-32 (fig. S4G), in line with the
notion that the relative ratio of IL-32 isoforms, but not their absolute
expression levels, determine susceptibility to infection.
Relative ratio of IL-32 isoforms regulates the
proinflammatory cytokine environment and influences
susceptibility of primary CD4+ T cells to HIV infection
Our results thus far demonstrated that the rs4349147 SNP resides with-
in an enhancer region, which, via long-distance interaction, regulates
the expression of the IL-32 promoter and controls the expression of dis-
tinct isoforms of IL-32 at the RNA level. We also showed that the
rs4349147 SNP–driven distinct expression profile of IL-32 RNA iso-
forms influences HIV infection susceptibility in the Jurkat model system.
However, Jurkat cells have been reported to undergo posttranscriptional
processing of several IL-32 isoforms at the protein level, resulting in gen-
eration of smaller IL-32 peptides (Fig. 1E and fig. S3F) (9), although the
expression of IL-32a is not effected (fig. S3F). Therefore, to validate our
results and to examine the functional consequence of the different IL-32
isoforms on HIV infection susceptibility in a more physiologically rele-
vant system, we moved to the in vivo relevant primary CD4+ T cell tar-
gets of HIV.
It has previously been reported that stimulation of activated primary
CD4+ T cells with purified IL-32g, but not with IL-32a, results in an
increased production of proinflammatory cytokines (10). We therefore
asked whether supplementing primary CD4+ T cells with recombinant
IL-32g (rIL-32g) or rIL-32a would have an effect on susceptibility to
HIV infection. CD4+ T cells were isolated from eight healthy donors
and stimulated with CD3-CD28–coated beads in the absence or pres-
ence of either rIL-32a or rIL-32g. After stimulation, luciferase activity
was evaluated as a measure of infection efficiency (Fig. 4A). Our
experiments in Jurkat cells indicated that rs4349147 has only moderate
effects on susceptibility to infection. Tomaximize thewindowof oppor-
tunity that would allowminor variations in infection susceptibility to be
observed while minimizing the influence of factors associated with viral
replication, cells were infected with single-round infectious viral parti-
cles. Furthermore, to recapitulate, at least in part, the complex mixture
of viral variants present at the infection, we used viral particles pseudo-
typedwith anX4 variant derived from the reference strainHXB2 and an
R5 Env variant derived from a primary isolate. Similar to what was ob-
served after exogenous expression of IL-32 isoforms in rs4349147 KO
Jurkat cells (Fig. 3H), we found that luciferase activity was significantly
increased in primary cells stimulated in the presence of rIL-32g, whereas
infection levels similar to untreated control cells were obtained after
stimulation with rIL-32a (Fig. 4B). As expected, treatment of primary
CD4+ T cells with rIL-32g, but not with rIL-32a, resulted in significant
increase in the transcription of the proinflammatory cytokine IL-8
(Fig. 4C). These data strongly support our observations in the Jurkat
T cell line, where the increased relative expression of IL-32a over
non-a isoforms reduced susceptibility to HIV infection. However, the
cellular receptor for IL-32 is not yet identified. Therefore, we could not
exclude the possibility that the rIL-32a is unable to enter into the cells.
To confirm that the observed HIV-1 infection phenotype is linked to
the exogenously provided distinct IL-32 isoforms and to ensure similar
exposure to IL-32 isoforms, primary CD4+ T cells were lentivirally
transduced to overexpress IL-32a, as well as the non-a isoforms b or
g, and subsequently infected with HIV according to the indicated sche-
matic (Fig. 4D and fig. S5B). We examined the proinflammatory
environment caused by exogenous overexpression of the specific IL-32
isoforms a and g using both intracellular cytokine staining (fig. S5C)Palstra et al., Sci. Adv. 2018;4 : e1701729 21 February 2018and cytokine arrays of the primary cell supernatants (fig. S5D and table
S5). Cytokine arrays demonstrated significantly increased levels of IL-32
(approximately 10- and 6-fold overexpression over control for IL-32a
and IL-32g, respectively) in the culture supernatant, confirming the IL-32
lentiviral overexpression system (fig. S5D).Although the level of IL-32a
was higher in the culture supernatants only, exogenous expression of
IL-32g resulted in the up-regulation of proinflammatory cytokines, in-
cluding IL-8, IL-6, IL-10, TNFa (tumor necrosis factor–a), and IFN-g
(interferon-g) (fig. S5D). Consistent with our data using rIL-32 iso-
forms, the proinflammatory cytokine environment generated by
IL-32g overexpression resulted in a significant increase in susceptibility
to HIV infection (shown for five subjects). Similar to IL-32g, overexpres-
sion of the non–IL-32a isoform b also resulted in increased sus-
ceptibility to HIV infection (fig. S5A).
Thus, in remarkable similarity to treatment of primary CD4+ T cells
with rIL-32a and rIL-32g, as well as to infections performed after exog-
enous expression of IL-32a and non–IL-32a isoforms in Jurkat cell lines,
lentiviral overexpression of non–IL-32a isoforms g and b, but not a, ren-
dered the cells more susceptible to HIV infection (Fig. 4 and fig. S5).
These results are consistent with the increased susceptibility to infec-
tion observed in rs4349147 G/− cells, which exhibit a lower expression
of IL-32a and higher expression of proinflammatory IL-32 isoforms,
and suggest that the rs4349147-A allele generates a subdued proinflam-
matory environment compared to rs4349147-G,which leads to reduced
susceptibility to HIV infection.DISCUSSION
Here, we demonstrate that the noncoding variant rs4349147, associated
with HIV susceptibility, resides in a DNA region that functions as a
long-distance enhancer element for the IL-32 gene, located approxi-
mately 10-kb downstream. Deletion of this DNA region results in ab-
rogation of IL-32 gene expression in Jurkat cells, whereas 3C
experiments demonstrated direct long-distance interaction between this
enhancer region and the IL-32 promoter. Because Jurkat cells heterozy-
gously harbor both rs4349147-A and rs4349147-G alleles, we were able
to examine the effect of each allele on IL-32 expression and HIV infec-
tion efficiency by generating single-allele KO clones using the CRISPR-
Cas9 technology. The presence of the rs4349147-A allele alone was as-
sociatedwith an increased relative expression of nonproinflammatorya
IL-32 isoform,whereas the rs4349147-G allele cells displayed a switch in
the relative expression of IL-32 isoforms to the proinflammatory non-a
isoforms. We found that the functional consequence of this switch in
IL-32 isoforms is enhanced lymphocyte activation, which directs
increased susceptibility to HIV infection.
IL-32 isoforms and HIV infection
IL-32 has previously been reported to play a role in HIV infection and
disease progression, although its precise role has remained controversial
(7, 8). Comparison of IL-32 expression levels in HIV-infected patients
and healthy individuals indicated a rise in IL-32 levels in peripheral
blood mononuclear cells (PBMCs), gut, and lymph nodes in different
stages of HIV infection (11–13). IL-32 was suggested to mediate im-
mune suppression by promoting the expression of immunosuppressive
molecules, leading to decreased immune activation and, as a consequence,
increased HIV replication (13). However, several pieces of evidence also
pointed to an inhibitory role for IL-32 inHIV replication; small interfering
RNA (siRNA) depletion of IL-32 in Jurkat, human embryonic kidney
(HEK) 293T, and latently infected U1 macrophage cell lines and infected7 of 13
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 PBMCs led to an increase inHIV replication (11, 14). IL-32 depletion also
caused a reduction in levels of TH1 cells and proinflammatory cytokines
including IL-6 and TNFa (14). Resolving these seemingly contradictory
observations on the function of IL-32 in the context of HIV replication,
IL-32 was proposed to play a dual immune regulatory role (13), inducing
an antiviral immune response primarily via type I and type III IFNs
(12, 15, 16) but also moderating immune activation duringHIV infec-
tion (13). The siRNA depletion studies relied on depletion of all iso-
forms of IL-32 (11, 14), and many studies have used RT-PCR primers
and antibodies that recognize common IL-32 sequences or epitopes
and do not distinguish between different IL-32 isoforms and their po-
tentially distinct functional roles in immune regulation.
Key to deciphering the role of IL-32 in immune function and regu-
lation, IL-32 exists in multiple isoforms, which, it is becoming increas-
ingly clear, are functionally distinct (17). IL-32a, which we found to be
predominantly expressed in rs4349147-A allele Jurkat cells, has been in
particular and in agreement with our findings, shown to be less potent
than either IL-32b and IL-32g isoforms in inducing a proinflammatory
state in PBMCs (18, 19). A recent study has shown that plasma levels ofPalstra et al., Sci. Adv. 2018;4 : e1701729 21 February 2018the proinflammatory non–IL-32a isoforms are correlated with higher
viral loads and significantly increased in HIV-infected slow progressors
that experience virological failure (10). In addition, consistent with our
data, IL-32g was shown to be a much more potent inducer of IL-6 and
IL-17F in CD4+ T cells than IL-32a (10). TH17 cells are known to be a
preferential target susceptible to HIV infection (20), although it is long
known that IL-6, alone or in combination with other cytokines, pro-
motes HIV replication in macrophages and latently infected CD4+ T
cells (21–23). Thus, as suggested by our cytokine array data comparing
the expression of proinflammatory cytokines induced by exogenous ex-
pression of IL-32a and IL-32g, one can envision that in vivo, the
rs4349147-G allele by its induction of IL-32g could augment the pro-
duction of IL-6 and other proinflammatory cytokines, producing a sus-
tained inflammatory environment ideal for HIV replication. rs4349147
is not readily picked up with high significance in HIV acquisition
GWASs, which indicates that the effect of rs4349147 is small and it is
not themain driver ofHIV resistance. Likewise in our study, looking only
at single rs4349147 alleles, we observe modest effects on IL-32 isoform
ratio and infection susceptibility, although the fact that these effectsFig. 4. Relative ratio of IL-32 isoforms influences susceptibility of primaryCD4+ T cells toHIV infection andalters theproinflammatory cytokineenvironment. (A) CD4+
T cells isolated fromeight healthy donorswere stimulatedwith CD3-CD28–coatedbeads in the presenceor absence of rIL-32a or rIL-32g and infectedwith anHIV virus harboring a
luciferase reporter, as shown in the schematic. Efficiency of infection was determined by measuring luciferase activity 72 hours after infection. (B) CD4+ T cells exogenously
incubated with rIL-32g are more susceptible to HIV infection than mock-treated cells and cells treated with rIL-32a. ns, not significant. (C) Real-time PCR analysis demonstrates
that CD4+ T cells incubated with rIL-32g, but not those treated with rIL-32a, show increased IL-8 expression. CypA, cyclophilin A. (D) CD4+ T cells isolated from five healthy donors
(rs4349147-G/A) were stimulated with CD3-CD28–coated beads and infected with a control lentiviral vector or a lentiviral vector expressing IL-32a or IL-32g. After 4 days, the cells
were restimulated for 24 hours and infected with an HIV virus harboring a luciferase reporter, as shown in the schematic. Efficiency of infection was determined by measuring
luciferase activity 72 hours after infection. (E) Exogenous lentiviral overexpression of IL-32g results in an increase inHIV infection as compared to CD4+ T cells overexpressing IL-32a
or control cells infected with an empty lentiviral construct. (F) Model depicting rs4349147 regulation of IL-32 expression. See Discussion for explanation.8 of 13
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 may be enhanced in individuals that carry homozygous G/G or A/A al-
leles of rs4349147 cannot be excluded. We therefore envision that
rs4349147nuances the combinatorial effect that includes the contribution
of additional host factors toward resistance to HIV acquisition.
Transcriptional regulation of IL-32 isoform expression
How the different alleles of rs4349147 (or the associated variant
rs4786376) modulate the activity of the IL-32 enhancer remains to be
understood. Bioinformatic transcription factor consensus site analysis
of the region using PROMO (http://alggen.lsi.upc.es/) indicated that
the rs4349147-G allele is part of a potential binding site for YY1 (Yin
Yang 1), STAT, and ETS (E26 transformation–specific) family tran-
scription factors, which are compromised when the rs4349147-A allele
is present. Because similar analysis of rs4786376 did not yield a potential
transcription factor binding site that is altered, rs4349147, and not the
linked rs4786376, is likely to be the functionally relevant allelewithin the
IL-32 enhancer. This is consistent with our data obtained in the luciferase
reporter assays where only the rs4349147-G variant is increasing the ex-
pression from the reporter construct. Data from genome-wide binding
studies performed in T cells indicate that STAT5, ETS, and other factors
of the TAL1 (T cell acute lymphocytic leukemia 1) complex (HEB, E2A,
LMO1, RUNX1, and GATA3) bind to the rs4349147 DHS (24–27). YY1
has been implicated in long-range chromatin interaction within the TH2
cytokine locus and V(D)J recombination in immature B cells (28, 29).
Which of the above transcription factors are involved in the long-range
regulation of IL-32 expression is the subject of an ongoing investigation.
The observed rs4349147 allele–specific switch in ratio of IL-32 iso-
form expression is in agreement with data from the International Hu-
man Epigenome Consortium that identified the IL-32 gene (among
others) as having a significant genetic and epigenetic contribution to
its expression levels and to its isoform expression in CD4+ T cells
(30). Our data provide mechanistic insight into this phenomenon: In
cells carrying only rs4349147-G, expression of “short” IL-32 variants
presumably originating from the downstream EPD IL32_1 promoter
is favored (most notably, variants that encode the proinflammatory
IL-32 isoforms). Conversely, expression of “long” IL-32 variants origi-
nating from the upstream EPDNK4_1 promoter is favored in cells that
contain the rs4349147-A allele [variants 2 and 8 encoding the B isoform
of IL-32 (IL-32b) and variant 4 encoding the A isoform of IL-32 (IL-
32a)]. This notion that these “long” and “short” IL-32 RNA transcripts
are transcribed using different promoters is supported by the presence
of a dual DNase I hypersensitivity peak at the IL-32 proximal upstream
region in T cells (fig. S6). The alternative use of promoters has long been
described to be a mechanism to generate diversity in transcriptional
output, as well as complexity and nuance in the regulation of gene ex-
pression (31). We envision three models that can explain the observed
IL-32 isoform switching. First, depending on its allelic nature, the
enhancer (rs4349147-G) contacts either the EPD IL32_1 “short” iso-
form promoter or the EPD NK4_1 promoter of the long IL-32 RNA
isoforms (rs4349147-A). Second, the rs4349147-G enhancer interacts
with the EPD IL32_1 promoter of the short IL-32 RNA isoforms, and no
interaction with either promoter is established when the rs4349147-A
allele is present. Third, the rs4349147-A enhancer interacts with the
EPDNK4_1 promoter of the long isoforms, and this interaction is lost
with rs4349147-G.Wedeem the latter scenario unlikely because a strong
reduction in IL-32 RNA expression is observed in rs4349147 −/A Jurkat
cells, suggesting that the enhancer element is no longer fully functional.
Unfortunately, 3C experiments lack the resolution to distinction be-
tween the two remaining models. However, 3C experiments indicatePalstra et al., Sci. Adv. 2018;4 : e1701729 21 February 2018a significant reduction in the interaction between the enhancer and
the general IL-32 promoter region, indicating a major change in the
chromatin conformation in rs4349147−/A Jurkat cells. In cell types that
are not DNase I–hypersensitive at the rs4349147 region but still express
low levels of IL-32, a major DHS peak is observed at the EPD NK4_1
promoter, which suggests that this is a “default” promoter for IL-32 ex-
pression (fig. S6). However, in cell lines lacking the rs4349147 regula-
tory element, IL-32 expression is strongly reduced compared to cells
containing the rs4349147-A allele, which indicates that in these cells,
the rs4349147 regulatory element still contains significant enhancer ac-
tivity. The switch in IL-32 promoter usage in rs4349147 −/A cells suggests
that this residual enhancer activity is now less focused, potentially by loss
of binding of a tethering transcription factor, on the EPD IL32_1 short
isoform promoter, which allows the EPDNK4_1 long isoform promoter
to profit from the nowmore promiscuous regulatory element. There-
fore, our results are consistent with themodel depicted in Fig. 4F, where
the rs4349147-G enhancer interacts with and specifically activates the
EPD IL32_1 promoter while this interaction is altered in rs4349147−/A
Jurkat cells, resulting in relatively increased IL-32 expression from the
EPD NK4_1 long isoform promoter and a relative increase in the ex-
pression of IL-32a. In the absence of the rs4349147 regulatory element,
IL-32 expression from both promoters is strongly reduced (Fig. 4F).
Implications for HIV GWASs
We took a three-step approach to demonstrate that HIV-1–associated
variants that fall below the accepted statistical threshold for genome-
wide significance can still have biological relevance. We collected
HIV-1–associated variants and compared them to epigenomic features
to extract the variants with potential biological function. This integra-
tion of GWAS data with epigenomic data allowed us to discriminate
true biological signals fromnoise. Promising candidate variants are sub-
sequently scrutinized by detailed molecular analysis to elucidate their
biological function. GWASs are geared to identify genetic variants with
relatively high minor allele frequencies and moderate to high effects,
especially when the sample size is small. As generally seen in HIV-
1 GWASs (1), which are underpowered because of the difficulty in col-
lection of large cohorts, rare variants and common variants with weak
effect size are missed because they fall below the stringent threshold for
genome-wide significance (P < 5 × 10−8). The study of Lingappa et al.
(4), which initially pointed out the association between the rs4349147
and HIV-1 susceptibility in discordant couples, was likely affected by
the low number of individuals included in the study. Furthermore,
our data underline amodest effect of rs4349147 onHIV-1 susceptibility,
which has likely further hampered the achievement of level of signifi-
cance. The general approach to identify rarer variants with a low effect
size is to enlarge the sample size (for example, by replication studies
and/or meta-analysis), which is not always practical and still can only
provide a statistical association and not actual biological relevance. Our
current study, as well as the work of others (3), provides an additional
approach to identify and characterize biologically important sub-
threshold variants.Using our approach, functional data can be extracted
from previous GWASs, which is of utmost importance to push the field
of HIV-1 host genetics forward.
In summary, we identify here, for the first time, themolecularmech-
anism by which a GWAS-identified HIV susceptibility allele functions.
Our findings underscore the power of using a combined approach in
which GWAS data and genome-wide functional data, together with
functionalmolecular andphenotypic analysis, are leveraged tounderstand
and unravel the underlying biological basis of disease. Our data provide9 of 13
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direct a switch in promoter usage and, as a consequence, modulate differ-
ential isoform expression. This can subsequently lead to complex pheno-
typic changes, such as, as we show for IL-32, differential susceptibility to
HIV infection but also potentially for other IL-32–related pathologies
such as viral and bacterial infections, cancer, rheumatoid arthritis, and
atherosclerosis (7). Our methodological approach can be expanded to
identify additional loci associated withHIV susceptibility, pathogenesis,
and latency, allowing the development of therapies and interventions
tailored to specific patient populations. o
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 MATERIALS AND METHODS
Cell culture and plasmids
Jurkat cells (a human T cell–derived line) were cultured in RPMI 1640
(Sigma-Aldrich) supplemented with 10% heat-inactivated fetal bovine
serum (FBS) and 1%penicillin-streptomycin. rIL-32a and rIL-32gwere
purchased from R&D Systems and resuspended according to the man-
ufacturer’s instructions. For the IL-32 overexpression constructs,
gBlocks gene fragments (IntegratedDNATechnologies) corresponding
to the complementaryDNA (cDNA) sequence of the corresponding IL-
32 isoformswere cloned into IRES-puro-GFP (a gift fromB.Vogelstein;
plasmid #16616, Addgene). Plasmidswere sequence-verified. pHR-SFFV-
KRAB-dCas9-P2A-mCherry was a gift from J. Weissman (plasmid
#60954, Addgene).
Analysis of GWAS SNPs
HIV/AIDS implicated DNA variants were retrieved from the GWAS
catalog (www.ebi.ac.uk/gwas/; June 2014). A total of 117 SNPs from
16 studieswere recovered, 59 ofwhichwere classified as intergenic/non-
coding. SNPs in strong LD (r2 > 0.8) were obtained from the CEU pop-
ulation panel of the 1000Genomes Pilot 1 andHapMap3 (release 2) data
sets using SNAP (SNP Annotation and Proxy Search) (http://archive.
broadinstitute.org/mpg/snap/; distance limit, 500 kb). Human hg18 ge-
nome coordinates were lifted to hg19 using the lift-over function in the
standard Galaxy tools of the Hypergenome browser (http://hyperbrowser.
uio.no/3d). CD4+ TH0 and TH1 DNase I hypersensitivity peaks (http://
genome.ucsc.edu/ENCODE/; wgEncodeAwgDnaseDukeTh0UniPk
and wgEncodeAwg DnaseDukeTh1UniPk) containing HIV-associated
SNPs were identified using the intersect function under Operate on Ge-
nomic intervals in the standard Galaxy tool, returning the overlapping
intervals. Fifteen and 16 DHS regions were recovered for TH0 and TH1
cells, respectively. Subsequently, the SNPs overlapping theseDHS regions
were retrieved using the join function under Operate on Genomic inter-
vals in the standardGalaxy tool, resulting in 17 SNPs for TH0 cells and 19
SNPs for TH1 cells, totaling 21 unique SNPs for both cell types (table S1).
Formaldehyde-assisted identification of regulatory elements
FAIRE was performed as described previously (32), except that selected
genomic sites were analyzed by quantitative real-time PCR using GoTaq
qPCR Master Mix (Promega) under the following cycling conditions:
95°C for 5 min, 45 cycles of 10 s at 95°C, and 30 s at 60°C, followed by
a melting curve analysis. Enrichment was calculated relative to Axin2,
and values were normalized to input measurements. PCR primers are
available on request.
Amaxa nucleofection
Nucleofection of Jurkat cell clones was conducted as described previ-
ously (33). Cells were split to 3 × 105 cells/ml 24 hours before AmaxaPalstra et al., Sci. Adv. 2018;4 : e1701729 21 February 2018nucleofection. Five to 8million cells were centrifuged at 1000 rpm for 10
min at room temperature, resuspended in 100 ml of solution R, and nu-
cleofected with 2 mg of expression plasmid using programO28. Nucleo-
fected cells were resuspended in 500 ml of prewarmed, serum-free RPMI
1640 lacking antibiotics and allowed to recover at 37°C in a 5% CO2
incubator for 15min. Prewarmed complete RPMI 1640 (4ml) was then
added to the cells.
Generation of rs4349147 KO cells using CRISPR-Cas9
The sgRNA cassette, the puro selection marker containing Cla I/Kpn I
fragment from pLKO.1-puro U6 sgRNA BfuAI large stuffer, was cloned
into pBluescript to yield pBS-puro U6 sgRNA BfuAI large stuffer. Oligos
for guide RNAs targeting the rs4349147 containingDHS region were de-
signed using ZiFiT (Zinc Finger Targeter) (http://zifit.partners.org/ZiFiT/
CSquare9Nuclease.aspx) (34) and cloned into theBfuAI sites of pBS-puro
U6 sgRNABfuAI large stuffer. Sequences for the oligos used are available
in table S6. sgRNA plasmids were conucleofeted with pSpCas9(BB)-2A-
Puro (PX459) into Jurkat cells. Nucleofected cells were treated with pu-
romycin (1mg/ml) for 24hours. After recovery, the polyclonal population
was single cell–sorted using a BD FACSAria III cell sorter. Clones were
screened for deletion of the rs4349147 DHS using PCR, and breakpoints
were sequenced. Selected clones displayed similar growth characteristics.
pLKO.1-puro U6 sgRNA BfuAI large stuffer was a gift from S.
Wolfe (plasmid #52628, Addgene). pSpCas9(BB)-2A-puro (PX459)
was a gift from F. Zhang (plasmid #48139, Addgene) (35).
Primer sequences
Primer sequences used in this study are available in table S6.
RNA sequencing
RNAwas isolatedusingTRIReagent (Sigma-Aldrich). RNA-seqwas per-
formed according to themanufacturer’s instructions (Illumina) using the
the TruSeq Stranded mRNA Library Prep kit. The resulting DNA li-
braries were sequenced according to the Illumina TruSeq v3 protocol
on an IlluminaHiSeq 2500 sequencer. Reads of 50 bp in lengthwere gen-
erated. Reads were mapped against the UCSC genome browser hg19
reference genomewith TopHat (version 2.0.10 or 2.0.13). Gene expression
was quantified using bothCufflinks (version 2.1.1) andHTSeq-count (ver-
sion 0.6.1). For the WT Jurkat and rs4349147 DHS KO samples, 13 to
18 million reads were generated, whereas approximately 20 million
reads were generated for the Jurkat rs4349147 −/A and G/− lines. In
all cases, more than 97% of these reads aligned to the hg19 genome. Dif-
ferential expression analysis of the RNA-seq data was performed using
edgeR package run under Galaxy (https://bioinf-galaxian.erasmusmc.nl/
galaxy/). False discovery rate cutoff was set to 0.05.
Heat maps were generated using MORPHEUS (https://software.
broadinstitute.org/morpheus/index.html). Enrichment of GO terms
for the differentially expressed genes was assessed using Enrichr
(http://amp.pharm.mssm.edu/Enrichr/) (36).
Western blotting
Whole-cell extracts were fractionated by SDS–polyacrylamide gel elec-
trophoresis and transferred to a polyvinylidene difluoride membrane
according to the manufacturer’s guidelines (Bio-Rad). Membranes
were blocked in 5% nonfat milk in PBST [phosphate-buffered saline
(PBS), 0.1% Tween 20] for 30 min and then washed three times in
PBST. Membranes were incubated with antibodies against IL-32
(513501, BioLegend; or MAB30401, R&D Systems), IL-32a (AF3040,
R&D Systems), and tubulin (1:1000; TS168, Sigma-Aldrich) overnight10 of 13
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 at 4°C. After washing the membranes three times for 10 min, they were
incubated with horseradish peroxidase–conjugated anti-mouse (A9044,
Sigma-Aldrich), anti-rat (A 9037, Sigma-Aldrich), or anti-goat (V8051,
Promega) antibodies for at least 1 hour. Membranes were washed three
times with TBST (tris-buffered saline, 0.1% Tween 20) and imaged
using ImageQuant LAS 4000 Mini (GE Healthcare) with SuperSignal
West Pico Chemiluminescent Substrate or SuperSignal Weste Femto
Maximum Sensitivity Substrate (34080 and 34095, respectively, Thermo
Fisher Scientific).
cDNA analysis
Total cellular RNA was isolated from the different cell lines with TriPure
Isolation Reagent according to the manufacturer’s instructions (Roche
Diagnostics). Subsequent DNase I digestion was performed with
amplification grade DNase I (Invitrogen). The reverse-transcriptase
reaction was performed using SuperScript II RNase H reverse tran-
scriptase (Invitrogen) according to the manufacturer’s instructions.
Quantitative real-time PCR reactions for gene expression analysis
were performed on a CFX96TM Real-Time System (Bio-Rad) with
the GoTaq qPCR Master Mix (Promega) using the following param-
eters: denaturation at 95°C for 5 min, followed by 40 cycles at 95°C for
10 s, and 60°C for 30 s, followed by a melting curve analysis. The
reference gene b2-macroglobulin or cyclophilin A was used to normalize
the amplification signal between the samples of different cell lines, dif-
ferences in treatment, and amount of input cDNA.
Intracellular stain
WT, rs4349147 −/A, rs4349147 G/−, and rs4349147 DHS KO Jurkat
clones were harvested, counted, and directly stained for intracellular
IL-32 expression. Briefly, 1 × 106 cells were first washed with Hanks’
balanced salt solution (HBSS)/3% FBS/0.015 M NaN3 and then fixed
with IC Fixation Buffer (eBioscience). After washing with HBSS/3%
FBS/0.015 M NaN3, cells were incubated with biotinylated anti-human
IL-32 antibody (clone Ku32-52, BioLegend) for 60min at 4°C, followed
by two washes with permeabilization buffer (eBioscience) and incuba-
tion with allophycocyanin (APC)–conjugated streptavidin (Thermo
Fisher Scientific) for 60 min at 4°C. Cells were also incubated with only
APC-conjugated streptavidin as control. Cells were washed twice with
permeabilization buffer and resuspended in 1% paraformaldehyde. A
total of 100,000 cells were collected per sample on an LSRFortessa flow
cytometry instrument (BD Biosciences) and analyzed using FlowJo
software (Tree Star).
3C analysis
3C analysis was performed as described previously (37, 38) using Dpn
II as the restriction enzyme. Quantitative real-time PCR (CFX96TM
Real-Time System, Bio-Rad) was performed using GoTaq qPCR
Master Mix (Promega) under the following cycling conditions:
50°C for 2 min, 95°C for 10 min, 45 cycles of 15 s at 95°C, and
1 min at 60°C, followed by a melting curve analysis. A random tem-
plate was generated as described previously (39) using gBlocks gene
fragments (Integrated DNA Technologies). PCR primers are available
in table S6.
Luciferase reporter assays
Custom 500-bp gBlocks gene fragments (Integrated DNA Technolo-
gies) containing different haplotypes of the enhancer regionwere cloned
into a modified pGL3-promoter vector [in which the SV40 promoter
and the SV40 3′ untranslated region (3′UTR) were replaced by thePalstra et al., Sci. Adv. 2018;4 : e1701729 21 February 2018IL-32 promoter and an HSP 3′UTR] (Promega). Jurkat cells are heter-
ozygous for two additional common variants within the hypersensitive
region: rs12598118 and rs12917910 (see fig. S1B). These variants are in
high linkage to each other but are linked to rs4349147 at a much lower
level, and there is no associationwithHIV acquisition reported for these
SNPs. The genotypes for rs12598118 and rs12917910were fixed to their
ancestral C alleles while we varied the alleles for rs4349147 and
rs4786376. Inserts in each construct were verified by sequencing (Base-
Clear). Constructs were nucleofected into Jurkat cells using the Cell
Line Nucleofector Kit R (Lonza) and an Amaxa Nucleofector device
(Lonza). Luciferase expression was measured after 24 and 48 hours in a
GloMax 96 microplate luminometer (Promega) and normalized to Re-
nilla luciferase expression. Data represent at least three independent
experiments. Student’s two-tailed t test was used to determine statistical
significance.
Virus production
HIV Env-pseudotyped particles were obtained by cotransfecting Env
together with the HIV-1 backbone plasmid (pNL4.3.Luc.R-E-) into
HEK 293T cells using FuGENE transfection reagent (Promega). To
produce X4 tropic–pseudotyped viruses, pNL4.3.Luc.R-E- was cotrans-
fected with HBXB2-Env expression construct, whereas cotransfection
with pTRO11 Env expression vector resulted in production R5 tropic
pseudoviruses. Twenty-four, 36, and 60 hours after transfection, the
pseudovirus-containing supernatant was collected, filtered through a
0.45-mm filter, aliquoted, and stored at −80°C. HIV-1 molecular clone
pNL4.3.Luc.R-E- and HIV-1 HXB2-Env expression vector were
provided by the Centre for AIDS Reagents, National Institute for
Biological Standards and Control. HIV-1 molecular clone pNL4.3.
Luc.R-E-, HIV-1 HXB2-Env, and pTRO11 Env expression vector
were donated byN. Landau;K. Page andD. Littman; andD.Montefiori,
F. Gao, and M. Li, respectively.
HIV-derived virus particles were generated as described previously
(40). Briefly, HEK293T cells were transfected with VSVG, the NL4.3
packaging vector R8.9, and the minimal HIV retroviral vector LTR-
Tat-IRES-EGFP (pEV731). Virus was harvested every 12 hours,
starting at 24 hours after transfection, filtered through a 0.45-mm filter,
aliquoted, and stored at −80°C. Plasmids used to generate HIV-
derived virus particles [VSV Env (VSVG), the NL4-3 packaging vector
(R8.91), and the retroviral vector LTR-Tat-IRES-EGFP (pEV731)]
were described previously (40).
HIV infection of Jurkat rs4349147 clones
Jurkat rs4349147 clones were infected with the minimal HIV VSVG-
pseudotyped virus at low multiplicity of infection such that less than
10% of cells were infected. Samples were analyzed on a Fortessa flow
cytometer with FACSDiva software (Becton Dickinson). The live pop-
ulation was defined by forward versus side scatter profiles. Cells were
further gated by using forward scatter versus green fluorescent protein
(GFP) to differentiate between GFP-positive and GFP-negative cells.
GFP expression in the Jurkat rs4349147 clones was analyzed by FACS
24 and 48 hours after infection.
For HXB2 HIV Env–pseudotyped virus infection, 500,000 cells
were infected by spinoculation (1200g, 90 min, 37°C), incubated in
a humidified 37°C, 5% CO2 incubator for 2 hours, washed, and
cultured for 48 hours in RPMI 1640/10% fetal calf serum (FCS). To
evaluate infection levels, luciferase activity was measured using Lucif-
erase Assay System (Promega). Relative light units were normalized to
protein content determined by Bradford assay (Bio-Rad).11 of 13
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 Primary CD4+ T cell isolation and infection
Primary CD4+ T cells were isolated from buffy coats from healthy do-
nors by Ficoll gradient, followed by magnetic separation with Rosette
Sep Human CD4+ T cell Enrichment Cocktail (STEMCELL Technolo-
gies) according to the manufacturer’s instructions. Cells were kept in
culture in RPMI 1640/10% FCS for 1week and subsequently stimulated
for 3 days with anti–CD3-CD28–coated beads and IL-2 in the absence
or presence of 500 ng/ml (10) of either rIL-32a or rIL-32g (R&D
Systems). After stimulation, cells were infected with a mixture of R5
and X4 Env-pseudotyped virus by spinoculation (1200g, 90 min, 37°C),
incubated in a humidified 37°C, 5% CO2 incubator for 2 hours, washed,
and then cultured in RPMI 1640/10% FCS supplemented with IL-2.
Seventy-two hours after infection, cells were harvested andwashed once
with PBS, and luciferase activity was measured using Luciferase Assay
System (Promega). Relative light units were normalized to protein con-
tent determined by Bradford assay (Bio-Rad).
Lentiviral overexpression of IL-32 isoforms
cDNAs encoding different isoforms of IL-32 were PCR-cloned into
Mlu I/Spe I restriction sites of the lentiviral vector pLenti6.3/V5-DEST
(Invitrogen). Virusparticleswereproducedusing theViraPowerLentiviral
PackagingMix (Invitrogen) according to the supplier’s recommendations.
Primary CD4+ T cells were isolated from buffy coats from healthy donors
by Ficoll gradient, followed by magnetic separation with Rosette Sep
Human CD4+ T cell Enrichment Cocktail (STEMCELL Technologies)
according to the manufacturer’s instructions. Cells were subsequently
stimulated for 3 days with anti–CD3-CD28–coated beads and IL-2. After
stimulation, cells were infected by spinoculation with IL-32a–, IL-32b–,
or IL-32g–expressing lentivirus. After 4 days, cells were restimulated for
24 hours and infected with an HIV virus harboring a luciferase reporter,
as described above. Seventy-twohours after infection, cellswere harvested
and washed once with PBS, and luciferase activity was measured using
Luciferase Assay System (Promega). Relative light units were normalized
to protein content determined by Bradford assay (Bio-Rad).
Intracellular cytokine detection
Purified CD4+ T cells were treated as described for the lentiviral IL-32
isoform overexpression. During the last 5 hours of the final bead acti-
vation step, a protein transport inhibitor (GolgiPlug, BD Biosciences)
was added to prevent the release of cytokines. Cells were harvested
and incubated with annexin V–phycoerythrin (PE) in FACS wash
(HBSS, 3% FBS, 0.02% NaN3, and 2.5 nM CaCl2) for 20 min at 4°C
in the dark. For intracellular staining for cytokines, cells were then fixed
(IC Fixation Buffer, eBioscience), washed (permeabilization buffer,
eBioscience), incubated with the antibodies (TNFa-APC, clone
MAb11; IFN-g–PE-Cy7, clone 4S.B3, eBioscience) for 45 min, washed
two times with permeabilization buffer, and fixed with 1% para-
formaldehyde. At least 100,000 events were collected per sample within
24 hours after staining on a LSRFortessa (BDBiosciences) and analyzed
using FlowJo software (Tree Star).
Proteome profiler Human XL Cytokine Array
Jurkat rs4349147 −/A and rs4349147 G/− clones or purified CD4+ cells
were grown to equal density (8 × 105 cells/ml for Jurkat cells and 2 ×
106 cells/ml for CD4+ cells). Cells were spun down, and 500 ml of super-
natant was incubated with the Human XL Cytokine Array membrane
(R&D systems). Membranes were processed according to the manufac-
turer’s instructions and imaged on a ImageQuant LAS 4000 (GE Health-
care). Signal was quantified using ImageQuant TL software (GEHealthcare).Palstra et al., Sci. Adv. 2018;4 : e1701729 21 February 2018Statistical analysis
All data are means ± SD of three or more independent biological re-
plicates. For 3C and cDNA qPCR experiments, comparison of fold
change data was performed by a Student’s two-tailed t test or by
one-way analysis of variance (ANOVA).
For infection experiments, comparison of fold change data was
performed by one-way ANOVA (Kruskal-Wallis test) using logarith-
mically transformed values. Statistical significance was reported as ns,
P > 0.05, *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/4/2/e1701729/DC1
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